FrancophonIA/ELRC3.0 huggingface dataset:
English: This could mean that your doctor needs to change the dose(s) that you take.
Danish: Dette kan betyde, at din læge er nødt til at ændre den dosis, du skal have.
English: CABOMETYX contains lactose (a type of sugar).
Danish: CABOMETYX indeholder lactose (en sukkerart).
English: Diarrhoea, nausea/vomiting, decreased appetite, and stomatitis/oral pain were some of the most commonly reported GI adverse reactions (see section 4.8).
Danish: Diarré, kvalme/opkastning, nedsat appetit og stomatitis/orale smerter var nogle af de hyppigst rapporterede GI-bivirkninger (se pkt.
English: Predisposing risk factors for severe haemorrhage in the advanced HCC population may include tumour invasion of major blood vessels and the presence of underlying liver cirrhosis resulting in oesophageal varices, portal hypertension, and thrombocytopenia.
Danish: Prædisponerende risikofaktorer for svær blødning i den fremskredne HCCpopulation kan omfatte tumorinvasion af store blodkar og tilstedeværelsen af underliggende levercirrhose, der resulterer i øsofageale varicer, portal hypertension og trombocytopeni.
English: • Swelling in your legs and arms
Danish: • Hævelse i dine ben og arme
English: Overall Survival Median OS in months (95% CI)
Danish: Samlet overlevelse Median OS i måneder (95% CI)
English: Hepatic effects Abnormalities of liver function tests (increases in alanine aminotransferase [ALT], aspartate aminotransferase [AST] and bilirubin) have been frequently observed in patients treated with cabozantinib.
Danish: Abnormiteter i leverfunktionstests (stigninger i alaninaminotransferase [ALAT], aspartataminotransferase [ASAT] og bilirubin) er blevet observeret hyppigt hos patienter behandlet med cabozantinib.
English: All events were Grade 3 or 4.
Danish: Alle hændelser var grad 3 eller 4.
English: In the treatment-naïve RCC study (CABOSUN), no cases of fistulas were reported.
Danish: I studiet af behandlingsnaivt RCC (CABOSUN) blev der ikke rapporteret tilfælde af fistler.
English: Randomization was stratified by aetiology of disease (HBV [with or without HCV], HCV [without HBV], or other), geographic region (Asia, other regions) and by presence of extrahepatic spread of disease and/or macrovascular invasions (Yes, No).
Danish: Randomisering blev stratificeret ved sygdomsætiologi (HBV [med eller uden HCV], HCV [uden HBV] eller andet), geografisk region (Asien, andre regioner) og ved forekomst af ekstrahepatisk sygdomsspredning og/eller makrovaskulære invasioner (Ja/Nej).
English: Following oral administration of cabozantinib, peak cabozantinib plasma concentrations are reached at 3 to 4 hours post-dose.
Danish: Efter oral administration af cabozantinib opnås cabozantinib-peak-plasmakoncentrationer 3 til 4 timer efter dosering.
English: NN:
Danish: Eller:
English: Method of administration CABOMETYX is for oral use.
Danish: CABOMETYX er til oral anvendelse.
English: Events were Grade 2 or 3.
Danish: Hændelserne var grad 2 eller 3.
English: Prolongation of QT interval
Danish: Forlængelse af QT-intervallet
English: CABOMETYX (cabozantinib) tablets and COMETRIQ (cabozantinib) capsules are not bioequivalent and should not be used interchangeably (see section 5.2).
Danish: CABOMETYX (cabozantinib)-tabletter og COMETRIQ (cabozantinib)-kapsler er ikke bioækvivalente og må ikke udskiftes indbyrdes (se pkt.
English: Prompt medical management, including supportive care with antiemetics, antidiarrhoeals, or antacids, should be instituted to prevent dehydration, electrolyte imbalances and weight loss.
Danish: Akut medicinsk behandling, herunder støttende behandling med antiemetika, midler mod diarré eller antacida, bør indledes for at forhindre dehydrering, elektrolytubalancer og vægttab.
English: What CABOMETYX is
Danish: Hvad CABOMETYX er
English: No cabozantinib-treated subjects in this study had a confirmed QTcF >500 ms, nor did any cabozantinib-treated subjects in the RCC or HCC studies (at a dose of 60 mg).
Danish: Ingen cabozantinibbehandlede patienter i dette studie havde en bekræftet QTcF >500 ms og heller ingen af de cabozantinibbehandlede patienter i RCC- eller HCC-studier (ved en dosis på 60 mg).
English: Cabozantinib should be used with caution in patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances.
Danish: Cabozantinib skal anvendes med forsigtighed til patienter med forlænget QT-interval i anamnesen, patienter, som tager antiarytmika, og patienter med allerede eksisterende hjertesygdom, bradykardi eller elektrolytforstyrrelser.
English: Kaplan-Meier landmark estimates of percent of subjects event-free at 3 months % (95% CI)
Danish: Kaplan-Meier-estimater af antal forsøgspersoner uden hændelser i % efter 3 måneder % (95 % CI)
English: If your next dose is due in less than 12 hours, then do not take the dose that you have missed.
Danish: Hvis der er mindre end 12 timer til din næste dosis, så lad være at tage den dosis, som du har glemt.
English: If adverse reaction resolves to Grade ≤1, re-initiate at a reduced dose.
Danish: Hvis bivirkningerne reduceres til grad ≤1, genstartes behandlingen ved en reduceret dosis.
English: Exploratory analyses of PFS and OS in the ITT population have also shown consistent results in favour of CABOMETYX compared to everolimus across different subgroups according to age (<65 vs. ≥65, sex, MSKCC risk group (favourable, intermediate, poor), ECOG status (0 vs. 1), time from diagnosis to randomisation (<1 year vs. ≥1 year), tumour MET status (high vs. low vs. unknown), bone metastases (absence vs. presence), visceral metastases (absence vs. presence), visceral and bone metastases (absence vs. presence), number of prior VEGFR-TKIs (1 vs. ≥2), duration of first VEGFRTKI (≤6 months vs. >6 months).
Danish: Eksplorative analyser af PFS og OS i intent to treat (ITT-) populationen har også vist konsistente resultater til fordel for CABOMETYX sammenlignet med everolimus i forskellige undergrupper i henhold til alder (<65 vs. ≥65, køn, MSKCC-risikogruppe (gunstig, middel, høj), ECOG-status (0 vs. 1), varighed fra diagnose til randomisering (<1 år vs. ≥1 år), tumor MET-status (høj vs. lav vs. ukendt), knoglemetastaser (fravær vs. tilstedeværelse), viscerale metastaser (fravær vs. tilstedeværelse), viscerale og knoglemetastaser (fravær vs. tilstedeværelse), antal tidligere VEGFR-TKIs (1 vs. ≥2), varighed af første VEGFR-TKI (≤6 måneder vs.>6 måneder).
English: Effective methods of contraception should be used by male and female patients and their partners during therapy, and for at least 4 months after completing therapy.
Danish: Mandlige og kvindelige patienter og deres partnere bør anvende effektive kontraceptionsmetoder under behandlingen og i mindst 4 måneder efter afsluttet behandling.
English: Patients with both positive and negative MET status showed a favourable effect with CABOMETYX compared to sunitinib, with greater activity in patients with a positive MET status compared to patients with a negative MET status (HR=0.32 (0.16, 0.63) vs 0.67 (0.37, 1.23)) respectively.
Danish: Både patienter med positiv og negativ MET-status opnåede en gunstig effekt af CABOMETYX sammenlignet med sunitinib, med større aktivitet hos patienter med positiv MET-status sammenlignet med patienter med negativ MET-status (HR = 0,32 (0,16; 0,63) vs 0,67 (0,37; 1.23)).
English: Objective response rate (ORR) findings are summarized in Table 5.
Danish: Objektive responsrate-værdier (ORR) er opsummeret i tabel 5.
English: In addition, cabozantinib inhibits other tyrosine kinases including the GAS6 receptor (AXL), RET, ROS1, TYRO3, MER, the stem cell factor receptor (KIT), TRKB, Fms-like tyrosine kinase-3 (FLT3), and TIE-2.
Danish: Derudover hæmmer cabozantinib andre tyrosinkinaser inklusive GAS6receptoren (AXL), RET, ROS1, TYR03, MER, stamcellefaktor-receptoren (KIT), TRKB, Fms-lignende tyrosinkinase-3 (FLT3) og TIE-2.
English: • Decrease in levels of; calcium, sodium and phosphate in the blood
Danish: • Nedsat mængde af calcium, natrium og fosfat i blodet
English: Cabozantinib is not recommended for use in patients with severe renal impairment as safety and efficacy have not been established in this population.
Danish: Cabozantinib anbefales ikke til patienter med svært nedsat nyrefunktion, da sikkerheden og virkningen ikke er blevet fastslået hos denne population.
English: Closer monitoring is advised in patients with mild or moderate hepatic impairment.
Danish: Tættere overvågning anbefales hos patienter med let eller moderat nedsat leverfunktion.
English: Patients who have a history of severe bleeding prior to treatment initiation should be carefully evaluated before initiating cabozantinib therapy.
Danish: Patienter, der har alvorlig blødning i anamnesen, skal evalueres omhyggeligt, inden behandling med cabozantinib initieres.
English: • Low level of albumin in blood
Danish: • Lavt indhold af albumin i blodet
English: RPLS is rare (it affects less than 1 in 1000 people).
Danish: RPLS er en sjælden bivirkning (påvirker færre end 1 ud af 1000 mennesker)
English: Two non-conjugated metabolites (XL184N-oxide and XL184 amide cleavage product), which possess <1% of the on-target kinase inhibition potency of parent cabozantinib, each represent <10% of total drug-related plasma exposure.
Danish: To ikke-konjugerede metabolitter (XL184-N-oxid og XL184-amid spaltningsprodukt), der har <1 % af cabozantinibs on-target kinasehæmningspotentiale, repræsenterer hver især <10 % af de samlede lægemiddelrelaterede plasmaeksponering.
English: Cabozantinib was evaluated for its inhibitory activity against a variety of kinases and was identified as an inhibitor of MET (hepatocyte growth factor receptor protein) and VEGF (vascular endothelial growth factor) receptors.
Danish: Cabozantinib er blevet evalueret for dets hæmmende aktivitet på en række kinaser og blev identificeret som en hæmmer af MET- (hepatocyt vækstfaktor-receptorprotein) og VEGF- (vaskulær endotelial vækstfaktor) receptorer.
English: Patheon France 40 Boulevard de Champaret 38300 Bourgoin-Jallieu FRANCE
Danish: Patheon France 40 Boulevard de Champaret 38300 Bourgoin-Jallieu FRANKRIG
English: • Abscess (collection of pus, with swelling and inflammation)
Danish: • Byld (ophobning af pus med hævelse og betændelse)
English: In a renal impairment study conducted with a single 60 mg dose of cabozantinib, the ratios of geometric LS mean for plasma cabozantinib, Cmax and AUC0-inf were 19% and 30% higher, for subjects with mild renal impairment (90% CI for Cmax 91.60% to 155.51%; AUC0-inf 98.79% to 171.26%) and 2% and 6-7% higher (90% CI for Cmax 78.64% to 133.52%; AUC0-inf 79.61% to 140.11%), for subjects with moderate renal impairment compared to subjects with normal renal function.
Danish: I et studie med nedsat nyrefunktion udført med en enkelt 60 mg dosis cabozantinb var ratioerne af middelværdierne for plasma-cabozantinib, Cmax og AUC0-inf var 19 % og 30 % højere hos forsøgspersoner med let nedsat nyrefunktion (90 % CI for Cmax 91,60-155,51 %; for AUC0-inf 98,79-171,26 %) og 2 % og 6-7 % højere (90 % CI for Cmax 78,64-133,52 %; for AUC0-inf 79,61-140,11 %) hos forsøgspersoner med moderat nedsat nyrefunktion sammenlignet med forsøgspersoner med normal nyrefunktion.
English: Cabometyx is not recommended for use in patients with severe hepatic impairment (Child-Pugh C) as cabozantinib has not been studied in this population and exposure might be increased in these patients.
Danish: CABOMETYX anbefales ikke til patienter med svært nedsat leverfunktion (ChildPugh C), da cabozantinib ikke er undersøgt i denne population, og eksponering kan være øget hos disse patienter.
English: Effect of cabozantinib on other medicinal products The effect of cabozantinib on the pharmacokinetics of contraceptive steroids has not been investigated.
Danish: Virkningen af cabozantinib på farmakokinetikken for kontraceptive steroider er ikke blevet undersøgt.
English: • Alopecia (hair loss and thinning), hair colour change
Danish: • Hårtab og udtynding af håret (alopeci), ændret hårfarve
English: This is because CABOMETYX can affect the way some other medicines work.
Danish: Dette skyldes, at CABOMETYX kan påvirke virkningen af visse andre lægemidler, ligesom visse andre lægemidler kan påvirke virkningen af CABOMETYX.
English: According to the Memorial Sloan Kettering Cancer Center criteria for prognostic risk category, 46% were favorable (0 risk factors), 42% were intermediate (1 risk factor), and 13% were poor (2 or 3 risk factors).
Danish: I henhold til kriterierne fra Memorial Sloan Kettering Cancer Center (MSKCC) for prognostisk risiko-kategori var 46 % i risikogruppen lav (0 risikofaktorer), 42 % var i risikogruppen middel (1 risikofaktor), og 13 % var i risikogruppen høj (2 eller 3 risikofaktorer).
English: The majority of the patients were male (78%) with a median age of 62 years.
Danish: Størstedelen af patienterne var mænd (78 %) med en medianalder på 62 år.
English: The median time to first dose reduction was 55 days, and to first dose interruption was 38 days.
Danish: Mediantiden var 55 dage til første dosisreduktion og 38 dage til førstebehandlingsafbrydelse.
English: Bile salt-sequestering agents such as cholestyramine and cholestagel may interact with cabozantinib and may impact absorption (or reabsorption) resulting in potentially decreased exposure (see section 5.2).
Danish: Galdesaltbindende midler såsom colestyramin og colesevelam kan interferere med cabozantinib og påvirke absorptionen (eller reabsorptionen), hvilket kan resultere i nedsat eksponering (se pkt.
English: Objective Response Rate n (%) by IRC Complete responses
Danish: Objektiv responsrate n (%) per IRC Fuldstændig respons
English: CABOMETYX blocks the action of proteins called receptor tyrosine kinases (RTKs), which are involved in the growth of cells and the development of new blood vessels that supply them.
Danish: CABOMETYX blokerer virkningen af proteiner, der kaldes receptor-tyrosinkinaser (RTK'er), og som er involveret i cellevækst og udvikling af nye blodkar til at forsyne celler.
English: In the 2-year rat carcinogenicity study, cabozantinibrelated neoplastic findings consisted of an increased incidence of benign pheochromocytoma, alone or in combination with malignant pheochromocytoma/complex malignant pheochromocytoma of the adrenal medulla in both sexes at exposures well below the intended exposure in humans.
Danish: I det 2-årige karcinogenicitetsstudie med rotter bestod de cabozantinib-relaterede neoplastiske fund af en øget forekomst af benignt fæokromocytom, alene eller i kombination med malignt fæokromocytom/komplekst malignt fæokromocytom i binyremarven hos begge køn ved eksponering langt under den tilsigtede eksponering hos mennesker.
English: Within a 48-day collection period after a single dose of 14C-cabozantinib in healthy volunteers, approximately 81% of the total administered radioactivity was recovered with 54% in faeces and 27% in urine.
Danish: Efter en enkelt dosis 14C-cabozantinib hos raske frivillige blev cirka 81 % af den samlede administrerede radioaktivitet genfundet inden for en indsamlingsperiode på 48 dage, med 54 % i fæces og 27 % i urin.
English: The safety and efficacy of CABOMETYX were evaluated in a randomized, double-blind, placebocontrolled Phase 3 study (CELESTIAL).
Danish: Sikkerheden og virkningen af CABOMETYX blev undersøgt i et randomiseret, dobbeltblindet, placebokontrolleret fase 3-studie (CELESTIAL).
English: Do not use this medicine after the expiry date which is stated on the blister, bottle label and carton after EXP.
Danish: Brug ikke lægemidlet efter den udløbsdato, der står på blister, tabletbeholderens etiket og pakningen efter Exp. Udløbsdatoen er den sidste dag i den nævnte måned.
English: The majority of the patients were male (75%), with a median age of 62 years.
Danish: Størstedelen af patienterne var mænd (75 %) med en medianalder på 62 år.
English: Cabozantinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumour growth and angiogenesis, pathologic bone remodeling, drug resistance, and metastatic progression of cancer.
Danish: Cabozantinib er et lille molekyle, der hæmmer multiple receptor-tyrosinkinaser (RTK'er) impliceret i tumorvækst og angiogenese, patologisk knogleremodellering, lægemiddelresistens og metastatisk progression af cancer.
English: Based on an integrated population pharmacokinetic analysis of cabozantinib in healthy subjects and cancer patients (including HCC), no clinically significant difference in the mean cabozantinib plasma exposure was observed amongst subjects with normal liver function (n=1425) and mild hepatic impairment (n=558).
Danish: Baseret på en integreret populationsfarmakokinetisk analyse af cabozantinib hos raske forsøgspersoner og cancerpatienter (herunder HCC), blev der ikke observeret nogen klinisk signifikant forskel i den gennemsnitlige cabozantinib-plasmaeksponering blandt forsøgspersoner med normal leverfunktion (n=1425) og let nedsat leverfunktion (n=558).
English: Cabozantinib should be discontinued in patients who develop an acute myocardial infarction or any other clinically significant thromboembolic complication.
Danish: Cabozantinib skal seponeres hos patienter, som udvikler akut myokardieinfarkt eller nogen anden klinisk signifikant tromboembolisk komplikation.
English: Each carton contains 4 blisters with 28 film-coated tablets.
Danish: Hver æske indeholder 4 blistere med 28 filmovertrukne tabletter.
English: Figure 4: Kaplan-Meier curve of overall survival (CELESTIAL)
Danish: Figur 4: Kaplan-Meier-kurve for samlet overlevelse (CELESTIAL)
English: Reversible Posterior Leukoencephalopathy Syndrome (RPLS)
Danish: Reversibelt posteriort leukoencefalopatisk syndrom (RPLS)
English: Repeat daily dosing of cabozantinib at 140 mg for 19 days resulted in an approximately a 4- to 5-fold mean cabozantinib accumulation (based on AUC) compared to a single dose administration; steady state is achieved by approximately Day 15.
Danish: Gentagen dosering af cabozantinib på 140 mg daglig i 19 dage resulterede i gennemsnitlig akkumulering af cabozantinib på ca. 4 til 5gange (baseret på AUC) sammenlignet med administration af en enkelt dosis; steady state opnås på ca. 15 dage.
English: Injury, poisoning and procedural complications wound complications
Danish: Traumer, forgiftninger og behandlingskomplikationer
English: A population PK analysis did not identify clinically relevant differences in PK of cabozantinib based on race.
Danish: En populationsfarmakokinetisk analyse identificerede ingen klinisk relevante forskelle i cabozantinibs farmakokinetik baseret på race.
English: • Decreased appetite, weight loss, altered sense of taste
Danish: • Appetitløshed, vægttab, ændret smagssans
English: Figure 5: Kaplan Meier curve for progression-free survival (CELESTIAL)
Danish: Figur 5: Kaplan Meier-kurve for progressionsfri overlevelse (CELESTIAL)
English: • Feeling drowsy, confused or loss of consciousness.
Danish: • Følelse af døsighed, forvirring eller tab af bevidsthed.
English: Reversible posterior leukoencephalopathy syndrome Reversible Posterior Leukoencephalopathy Syndrome (RPLS), also known as Posterior Reversible Encephalopathy Syndrome (PRES), has been observed with cabozantinib.
Danish: Der er blevet observeret reversibelt posteriort leukoencefalopatisyndrom (RPLS), også kendt som posteriort reversibelt encefalopatisyndrom (PRES) med cabozantinib.
English: Data for the following reactions are based on patients who received Cabometyx 60 mg qd po in the pivotal studies in RCC following prior VEGF-targeted therapy and in treatment-naïve RCC and in HCC following prior systemic therapy (section 5.1).
Danish: Data for nedenstående bivirkninger er baseret på patienter, der fik Cabometyx 60 mg oralt dagligt i de pivotale studier i RCC efter tidligere VEGF-målrettet behandling og i behandlingsnaivt RCC og i HCC efter forudgående systemisk behandling (pkt.
English: What you need to know before you take CABOMETYX 3.
Danish: Det skal du vide, før du begynder at tage CABOMETYX 3.
English: HDPE bottle with a polypropylene child-resistant closure and three silica gel dessicant canisters.
Danish: HDPE-tabletbeholder med en børnesikret polypropylenlukning og tre små dåser med silicagel som tørremiddel.
English: Each film-coated tablet contains 15.54 mg lactose.
Danish: Hver filmovertrukne tablet indeholder 15,54 mg lactose.
English: A statistically significant improvement in PFS as retrospectively assessed by a blinded Independent Radiology Committee (IRC) was demonstrated for CABOMETYX compared to sunitinib (Figure 3 and Table 5).
Danish: En statistisk signifikant forbedring i PFS, som efterfølgende blev vurderet af en blindet, uafhængig radiologisk komité (IRC), blev påvist for CABOMETYX sammenlignet med sunitinib (figur 3 og tabel 5).
English: CABOMETYX tablets are available in packs containing either 4 blisters with 7 tablets each (28 total), or one plastic bottle with 30 tablets.
Danish: CABOMETYX tabletter fås i pakninger med 4 blisterkort med 7 tabletter pr. stk. (28 tabletter i alt) eller en plastiktabletbeholder med 30 tabletter.
English: Each film-coated tablet contains 31.07 mg lactose.
Danish: Hver filmovertrukne tablet indeholder 31,07 mg lactose.
English: Therefore, cabozantinib may have the potential to increase plasma concentrations of co-administered substrates of P-gp.
Danish: Cabozantinib kan derfor have potentialet til at øge plasmakoncentrationen af samtidigt administrerede P-gp-substrater.
English: A statistically significant improvement in OS was demonstrated for CABOMETYX compared to placebo (Table 6 and Figure 4).
Danish: En statistisk signifikant forbedring i OS blev påvist for CABOMETYX sammenlignet med placebo (tabel 6 og figur 4).
English: Women of childbearing potential/Contraception in males and females Women of childbearing potential must be advised to avoid pregnancy while on cabozantinib.
Danish: Kvinder i den fertile alder/antikonception hos mænd og kvinder Kvinder i den fertile alder skal opfordres til at undgå at blive gravide, mens de får cabozantinib.
English: Patients (N=707) with HCC not amenable to curative treatment and who had previously received sorafenib for advanced disease were randomized (2:1) to receive CABOMETYX (N=470) or placebo (N=237).
Danish: Patienter (n=707) med HCC, der ikke kan behandles med kurativ behandling og som tidligere havde fået sorafenib til fremskreden sygdom, blev randomiseret (2:1) til at få CABOMETYX (n=470) eller placebo (n=237).
English: In the case of persistent hypertension despite use of anti-hypertensives, the cabozantinib dose should be reduced.
Danish: I tilfælde af vedvarende hypertension på trods af behandling med antihypertensiva skal cabozantinibdosis reduceres.
English: In rabbits, cabozantinib produced foetal soft tissue changes (reduced spleen size, small or missing intermediate lung lobe) and increased foetal incidence of total malformations.
Danish: Hos kaniner fremkaldte cabozantinib ændringer i føtale bløddele (reduceret miltstørrelse, lille eller manglende intermediær lunge-lap), og det totale antal misdannelser hos fostrene var øget.
English: • Low level of platelets and white blood cells
Danish: • Lavt antal blodplader og hvide blodlegemer
English: • Feeling drowsy, confused or loss of consciousness due to liver problems
Danish: • Følelse af døsighed, forvirring eller tab af bevidsthed på grund af leverproblemer
English: Clinical data in treatment-naïve renal cell carcinoma
Danish: Kliniske data ved behandlingsnaivt nyrecellekarcinom
English: Patients (N=658) with advanced RCC with a clear cell component who had previously received at least 1 prior VEGF receptor tyrosine kinase inhibitor (VEGFR TKI) were randomized (1:1) to receive CABOMETYX (N=330) or everolimus (N=328).
Danish: Patienter (N=658) med fremskreden RCC med en clearcelle-komponent, der tidligere havde fået mindst 1 VEGF-receptor-tyrosinkinasehæmmer (VEGFR TKI), blev randomiseret (1:1) til at få CABOMETYX (N=330) eller everolimus (N=328).
English: You should not eat anything for at least 2 hours before taking CABOMETYX and for 1 hour after taking the medicine.
Danish: Du må ikke spise noget mindst 2 timer, før du tager CABOMETYX, og 1 time efter, du har taget medicinen.